TVRD: Nilai perusahaan marang bathi resik Cara Pharma

This chart illustrates the price action of Cara Therapeutics Inc (TVRD), which automates the synthesis of anti-itch agents using IT algorithms, although final control remains with physicians. Meanwhile, Cara Therapeutics Inc (TVRD) is implementing ESG standards in its laboratories and strictly adhering to bioethics. The current PE ratio is -0.50. The business currently relies on external investments, as profitable products have not yet been brought to market.
Rincian analitis perusahaan Cara Therapeutics Inc

Cara Therapeutics Inc (TVRD) vulnerability to late-stage clinical trial failures for kidney drugs makes the business extremely sensitive to external shocks. Dependence on a single product amplifies risks when facing pharma behemoths, necessitating strict control over entry costs. The payback ratio measures the capital return period through the lens of current earnings, determining the asset's fundamental overvaluation. By analyzing the historical P/E of Cara Therapeutics Inc (TVRD), an investor can identify dangerous gaps between the market price and the business's actual ability to generate income.